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Psychotropic medications and crash risk in older drivers – a review of the literature  
Driving is a complex task where the driver continuously receives information, analyses it and reacts. 
Substances that have an influence on brain function or the mental processes involved in driving will 
clearly affect driving performance. The role of drugs other than alcohol, particularly medications, has 
not been well established and there is limited current evidence-based literature. By 2030, one out of 
four drivers will be aged 65 years, with estimates that over the next three decades fatal crashes 
could be as much as three times higher among older drivers unless there is active intervention.1 
These statistics plus the increasing number of older drivers on the road has generated concern 
among road safety experts. While older drivers are involved in fewer crashes compared with other 
driver age groups, their crash risk is equivalent to that of young drivers when driving exposure is 
taken into account.2-4 They are also more likely to be responsible for these crashes. 
Additionally, the older population has a higher prevalence of medical conditions and thus, a 
greater prevalence of medication use.5-6 Older drivers involved in a crash are more likely to be taking 
medications that can impair central nervous system functioning and impact on driving ability.5 
Furthermore, polypharmacy is more prevalent among the elderly than younger age groups and 
within the older driver group (65+ years), the use of such medications has been shown to increase 
with advancing age.5 Therapeutic effects of these medicines such as loss of psychomotor 
coordination, balance disturbance and somnolence may have detrimental effects on driving 
performance.7 Psychotropic medications include antidepressants, anxiolytic sedatives, 
benzodiazepines, some antihistamines, opioid analgesics, antiepileptics, antipsychotics and some 
medications for Parkinson’s disease.8-10 For the purpose of this review, only the commonly-
researched medications of hypnotic and sedating benzodiazepines and antidepressants were 
examined. Past research has found that the use of psychotropic (or psychoactive) drugs may 
adversely affect the ability of the older driver to safely operate a motor vehicle.10-13 However, many 
studies examining the relationship between these medicines and their impact on driver performance 
and crash risk have often been limited in their findings due to different methodologies, small sample 
sizes and selection bias.   
This comprehensive literature review examines Australian and international research, 
focussing on the association between sedating medications that act on the central nervous system 
and motor vehicle crash involving older drivers, 65 years and older. The identification of medications 
associated with an increased crash risk will provide clinicians and road safety stakeholders with the 
evidence base to address the important issue of safe driving for this group. 
METHODS 
A search of electronic databases (MEDLINE, PROQUEST and SCIENCEDIRECT) was conducted from 
March 2010 to April 2010. Reference lists of key articles were also viewed and searched for 
specifically. GOOGLE SCHOLAR was accessed via the internet for definitions and related articles. Key 
words searched included all possible versions of ‘crash risk, ‘road crashes’ ‘accidents’ ‘motor vehicle 
crash’ ‘road accidents’ in combination with ‘psychotropic medicines” (with such medications listed 
specifically including ‘benzodiazepines’, ‘anxiolytics’, ‘antidepressants’ and ‘hypnotics’);  and/or, 
‘older drivers’, ‘ageing population’ and ‘aged drivers’. Words and phrases were joined in order to 
explore appropriate available literature.  
The inclusion criteria comprised a priority focus on older adults (65+years) who held a driving 
licence and were taking psychotropic medication, and studies that addressed at least one of the 
following research questions: 
 What is the prevalence of psychotropic medications use amongst older drivers? 
 What are the side effects of driving under the influence of psychotropic medications? 
 What is the association between crash risk and psychotropic medications for older drivers? 
Studies limited to involvement of illicit drugs and alcohol only; studies of injury risk other than 
road traffic crashes; non-English articles; and articles pre-dating 1979, were excluded.  
RESULTS 
A total of 1634 articles were screened; of these, 127 full-text articles were reviewed (Fig. 1). Six 
experimental studies and 16 epidemiological studies were reviewed in detail and their 
methodologies and main results are summarised in Tables 1 and 2. A total of 106 national and 








Figure 1. Flowchart of the process of article selection for inclusion in review 
 
Prevalence of driving under the influence of Psychotropic Medications 
Research on the prevalence of driving while under the influence of medications among the general 
population is limited, particularly in Australia. There is however, more research conducted on crash-
involved drivers and drivers suspected of impaired driving.14 Most of these study outcomes do not 
allow for comparison between countries due to different methodologies. However, Walsh et al.15 
estimates the prevalence of licit drugs affecting driver performance in European countries is 
between 5-10% of the general driving population, which is higher than the estimated illicit drug use 
(1-5%).16 
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Blood or urine samples of injured or killed drivers are used to determine the presence of 
drugs. De Gier17 concluded that in Europe, benzodiazepines were the most frequently detected licit 
drugs other than alcohol. Studies of drivers stopped for suspicion of driving under the influence, 
reported benzodiazepines prevalence varied between 13-75%.17 Similar findings were reported in 
Australia where approximately half the drivers tested positive for benzodiazepine use.18 In a more 
recent 10-year Australian study of 3,398 fatally injured drivers in three states, Drummer and 
colleagues8 reported the incidence of drugs other than alcohol and comprised opioids (4.9%), 
benzodiazepines (4.1%), and other psychotropic drugs (2.7%). They reported drivers with 
benzodiazepines at therapeutic concentrations and above, had a significant increase in driver 
culpability.8, 16 Walsh and colleagues15 confirm a lack of data on the prevalence of drug utilisation in 
the general driving population. They suggest, however, that the high prevalence of drug use found in 
collision-involved drivers supports the assumption that this is a serious road safety concern. 
In an Australia-wide study, it was found to be as high as 10.6%. As many as 16.2% of the 
total sample population aged over 65 years (n=552) in the South Australian study (n=3015) were 
prescribed psychotropic medication.19 This is consistent with results from a previous Sydney-based 
study on benzodiazepine use in the elderly which reported a prevalence of 16.6% using 
benzodiazepine on a long-term basis.20 Such use is likely to increase with an ageing population.  
Paradoxically, although elderly people living in the community have a lower prevalence of 
affective anxiety disorders than younger adults, they have a much higher use of psychotropic 
drugs.20  This is possibly due to a higher prevalence of sleeping disorders and chronic physical illness 
among the elderly. Physical diseases and conditions reported to be associated with psychotropic 
drug use include cancer, heart disease, pulmonary disease, arthritis and musculo-skeletal pain. 
 
Effects of Psychotropic Medications on Driving Performance 
Benzodiazepines: Benzodiazepines possess sedative, hypnotic and anxiolytic actions and are the 
most frequently prescribed medication for the treatment of sleep and anxiety disorders.7, 21 It is 
generally recommended in older adults, that benzodiazepines with a longer half-life be avoided due 
to residual sedative effects and an association with falls, motor vehicle crash and impaired 
memory.22 Adverse effects of benzodiazepines on the central nervous system include drowsiness, 
confusion, dizziness, reduced motor coordination and impaired memory.14, 21 
Antidepressants: Antidepressants are prescribed to treat affective disorders such as depression, 
panic disorders, phobias and obsessive-compulsive disorders.7 Evidence suggests the sedating 
qualities of tricyclic antidepressants cause impairments in tasks related to driving skills for healthy 
individuals.23-25 Certainly, the initial start up time or adjustment of prescription increases the risk of 
driver impairment while taking antidepressants.25  This is also true for any rapid increase in dose or 
polydrug-use, particularly benzodiazepines.25 The side effects of tricyclic compounds are more 
severe than the newer antidepressants which cause less impairment in tests of psychomotor 
function.7, 23, 26 Side effects relating to driving impairment include drowsiness, blurred vision, 
dizziness, confusion and weakness. Adverse reactions may depend upon dosage and susceptibility to 
side effects may be related to age.21 
 
Association of Psychotropic Medications and Crash Risk  
Although it is difficult to measure the causal role of psychotropic drugs in motor vehicle crashes, 
their use increases the risk of crash involvement.11, 27-28 Concentration, information processing, 
alertness, an ability to perceive hazards and identify risk-taking behaviour, decision-making and 
ongoing sensorimotor control are required at all times during the operation of a motor vehicle29 and 
any impairment of driving often results in either traffic infringements or traffic crashes.   
To date, experimental laboratory-based, driving simulator and on-road driving studies have 
provided quite conclusive evidence that psychoactive medications can have detrimental effects on 
psychomotor and cognitive skills required for driving.30-31 However, the majority of these 
experimental studies have been conducted on small samples of young, healthy volunteers; meaning 
the findings may not apply to older drivers. These studies have also mostly assessed the effects of 
acute use of the medications on driving skills when many older drivers would be on stable regimes of 
medication.  
Experimental studies have shown adverse effects of many drugs on driving in controlled 
environments.23, 32-36 It has been largely demonstrated that residual effects of benzodiazepine 
hypnotics impair memory, psychomotor performance and driving performance.32, 35 Often a dose-
dependent impairment of driving was demonstrated in these studies with higher risks during initial 
use compared to chronic use.34, 37-38 Benzodiazepine anxiolytics were also found to be sedative and 
seriously deteriorated driving ability in two recent studies.34-35 
Epidemiological studies, despite reporting mixed results have also indicated increased 
probability of crash involvement for drivers taking some psychoactive medications.30, 39-40 Evidence is 
limited, however, for several reasons. Firstly, despite these medications being most commonly used 
by the older population, few epidemiological studies have either included or examined older drivers 
separately in their samples. Several of the studies that have examined older drivers however, are 
limited by small sample sizes, selection bias and have examined the effect of large groups of 
medications on crash risk rather than individual drugs. Epidemiological data clearly indicate that 
hypnotic benzodiazepines have been detected in a significant percentage of drivers involved in road 
crashes.37, 41-42 Vingilis and MacDonald36 reported that benzodiazepine users are up to six times more 
likely to be involved in road crashes than non-users.  Vermeeren43 reported inconsistent findings of 
association with increased road crash risk in regards to hypnotics. This inconsistency related to the 
specific drug, dose administered and patient characteristics but agreed that hypnotics could increase 
the risk of traffic crashes, whereas with anxiolytics, significantly increased risk in both the young and 
elderly drivers. This is supported by the findings of Ray et al.44 that report increased risk of traffic 
crashes for elderly users of benzodiazepine anxiolytics. Conversely, no such association was found by 
Leveille et al.45  Additionally, Hemmelgarn et al.13, who made the distinction between long and short 
half-life benzodiazepines, reported an associated risk for elderly drivers who used long half-life 
benzodiazepines but not for benzodiazepines with a short half-life.  
Several studies have specifically examined the risk for older drivers and, of seven 
epidemiological studies identified, four reported increased risk with benzodiazepine use. Two 
population-based studies in the USA both reported that benzodiazepine use was associated with 
crash involvement or at-fault crashes in drivers aged 65 and over.46-47 Neutel38 also reported an 
increased risk of injurious crashes for drivers aged 60 years and over, who used benzodiazepines in 
Canada. Interestingly, the risk was slightly lower for drivers aged over 60 years than those under.48 A 
Canadian-based nested case-control study of drivers aged 67-84 years examined the use of long and 
short half-life benzodiazepines and injurious crashes.49 They reported a significant increased risk of 
crash involvement within the first week of long half-life benzodiazepine use (rate ratio: 1.45, 95% CI: 
1.04-2.03) and a slightly lower but significant increased risk with continuous use up to one year (rate 
ratio: 1.26, 95% CI: 1.09-1.45). Neither initiation nor continued use of short half-life benzodiazepines 
affected crash risk in this group.49  
In contrast, an earlier case-control study in the USA reported no association between 
benzodiazepine use and injurious crash for older drivers.45 A case-crossover study also found that 
benzodiazepine use increased the risk of crash involvement for younger drivers but that risk 
decreased with age and was not significant for drivers aged over 65.39 This finding may be due to an 
artefact of the case-crossover method. Similarly, a recent case-control study reported that 
benzodiazepine use did not increase the odds of crash responsibility for drivers aged 65 and over for 
short, intermediate or long half-life benzodiazepines.50 However, drivers aged 25-55 years taking 
intermediate or long half-life benzodiazepines did experience increased odds of crash responsibility. 
Those taking short half-life benzodiazepines did not demonstrate increased odds.50 This study only 
examined fatal crashes however, and the authors acknowledge that the analyses may have lacked 
statistical power for drivers aged 65 and over.50  
Overall, evidence indicates that benzodiazepine use does increase the risk of crashes in both 
older and younger drivers. Again however, it is difficult to determine whether these crashes should 
be attributed to the effects of the medication or the disorders they are prescribed for such as 
sleeping problems or anxiety. The findings point to certain factors that may increase the risk of 
crashes including the use of intermediate and long half-life as opposed to short half-life 
benzodiazepines.39 In addition, a dose-response relationship has been reported and risk may be 
higher during initiation of the medication and decrease as tolerance to the medication develops.39, 49 
While studies examining benzodiazepines in general provide useful data, this encompasses a very 
broad group of medications including anxiolytics and hypnotics that may exert quite different and 
specific effects on driving ability.  
Walsh and colleagues’15 research suggest that at high doses, almost all benzodiazepines will 
cause some impairment.16, 51 Furthermore, an increased risk of crash occurs when taken above 
therapeutic doses or with alcohol.16 Kelly et al.14 reported findings from previous studies suggesting 
impairment may be limited to the early stages of benzodiazepine uptake,16, 33, 41 supporting the 
theory that a tolerance level may negate the impairment affects of the drug. Some studies have 
found that impairing effects diminish over time, as patients develop tolerance. However, the 
majority of studies do find dose-related impairments in driving-related skills.52 
Several studies have examined the association between the use of sedating anti-depressants 
(including tricyclic anti-depressants) and driving impairment or crashes. An early cohort and case-
crossover study conducted in the USA reported that the risk of injurious crash involvement in 65-84 
year old drivers was significantly increased for current users of tricyclic anti-depressants (RR: 2.2; 
95% CI 1.3-3.5). This risk was dose-dependent with results showing that doses of amitriptyline ≥ 
125mg daily increased the risk of involvement in a crash by six times.47 Another USA-based case-
control study of drivers aged 65 years and older reported similar findings with participants who were 
taking tricyclic anti-depressant experiencing increased odds of a motor vehicle crash of 2.3 (95% CI: 
1.1-4.8).45 More recently, a population-based cohort study in Norway reported a slight but 
significant increase in crash involvement for drivers who had received prescriptions for sedating anti-
depressants including tricyclic anti-depressants (standardised incidence ratio: 1.4).53 However, this 
study only included drivers aged 18-69 years. In contrast, a case-crossover study conducted in the 
UK showed no increased risk of crashes with the use of tricyclic anti-depressants but the analysis 
included drivers 18 years and older and did not focus on older drivers.39 
The European Monitoring Centre for Drugs and Drug Addiction51 reported an association 
with the use of tricyclic antidepressants and impaired driving performance.  They found, however, 
no such impairment with new generation antidepressants.16 Leville et al.45 and Ray et al.54 also 
reported this increased risk, particularly for older drivers (RR= 2.3).16, 55 This was also supported by 
Bramness et al.56 who found an increased risk for drivers who were taking antidepressants.  He 
found a slightly higher risk for younger drivers.55 In contrast to this, Barbone et al.37 found no such 
relationship for drivers taking either selective serotonin reuptake inhibitors or tricyclic 
antidepressants.  This could suggest the risk is specific to older drivers.55 The newer non-sedating or 
non-tricyclic anti-depressants including selective serotonin reuptake inhibitors and serotonin 
norepinephrine reuptake inhibitors are thought to produce less side effects. While a few studies 
have reported slight increased risk of crash involvement53 and reduced driving performance,57 
several have reported that non-sedating anti-depressants do not impair driving or increase crash 
risk.39, 58-59 
 
Psychotropic Medications, Crash Risk and the Older Driver 
Scientific literature acknowledges that psychotropic medications can have a harmful effect on 
central nervous system responses, and thus, the psychomotor skills required for operating a 
vehicle.5, 9, 11, 42 This is particularly true for older drivers who tend to experience adverse drug 
reactions more intensely.5, 60  This is explained by reduced hepatic and renal function in the elderly 
along with a reduced ability to metabolise drugs efficiently.60 Elderly drivers are more likely to have 
chronic medical conditions and more likely to be taking medications affecting driving performance 
than younger drivers.  
The types of crash occurrence involving older drivers differ from those in younger age 
groups.  The older driver is more likely to be involved in slow moving, right of way traffic crashes.60  
This suggests a difficulty with decision-making requiring perceptual and cognitive functions. Frailty is 
also associated with more adverse side effects61 and may contribute to the older driver incurring 
more serious or fatal injuries when involved in road crashes62. With an ageing population, the 
number of drivers over the age of 65 years is certain to increase along with the increase in risk of 
serious or fatal motor vehicle crash. Historically, the elevated rate of motor vehicle crash involving 
older drivers has been attributed to the changes associated with ageing, such as visual impairment 
and delayed reaction time. However, recent literature has questioned this and suggested the intake 
of prescription and non-prescription psychotropic medicines may be an added causal factor. 
 
DISCUSSION 
While the current literature shows relatively limited knowledge of the prevalence of psychotropic 
drugs in road traffic compared to the knowledge regarding prevalence of alcohol in drivers, it is clear 
that driving under the influence of drugs is a worldwide problem. Research into the effects of 
prescription medication on drivers has not received the consideration it deserves. This is an 
emerging public health issue that has only in the past three decades been supported in some way by 
research. Operating a vehicle while impaired by drugs, whether licit or illicit, is increasingly becoming 
a community concern. Attention needs to be focused on this issue so that evidence-based 
information can be used to provide guidelines and education for the community on the effects of 
drugs on driving. 
It is evident from the literature that drugs are frequently detected in crash-involved drivers 
and that impaired driving is a significant cause of human trauma. However, results from laboratory, 
simulator and on-road tests indicate that the effect of medications on driver skills can vary between 
individuals depending on the interactions of age, gender, health condition and prescription use.29 
Medication effects will also be influenced by dosage, polypharmacy, tolerance levels and the time 
since intake.14, 29 Understanding the degree of reduced driving capability caused by psychotropic 
medications presents a major challenge for road safety experts. The principal drugs of concern are 
those which can affect a person’s ability to react to external stimuli, leading to impairment of driver 
skills. 
It is apparent that high doses of psychotropic medications, polypharmacy and drugs used in 
combination with alcohol are all likely to produce a significant threat to road safety.14 More 
knowledge about the traffic safety of therapeutic psychotropic medications is needed.  The main 
concern seems to be with benzodiazepines and related sedative or hypnotic drugs, and to a lesser 
extent tricyclic antidepressants but this may be due to lack of research in these areas.9 
Older drivers are more likely to sustain serious or fatal injury than younger drivers given the 
same crash conditions. While the safety of older drivers is important today, it will become even 
more important in the near future as the population ages. Public health initiatives to reduce the 
morbidity and mortality of older drivers should be vigorously pursued. 
 
Limitations of Past Research 
Although evidence indicates that several types of psychotropic medications have the potential to 
impair driving ability and increase the risk of crash involvement, a major limitation is that few have 
examined their effects specifically on older drivers. Despite the fact that the majority of the 
population using psychotropic medications are older,63 most experimental studies have been 
conducted using healthy, young volunteers and few epidemiological studies have included or 
analysed older drivers separately. 
A number of experimental studies have assessed the driving abilities of older drivers using 
psychotropic medications through laboratory tests, driving simulators or on-road driving 
assessments. While such studies suggest the potential impact of medications on driving ability, they 
do not take into account the impact of real life conditions that translate to actual crash involvement 
for older drivers.55 Therefore, epidemiological studies provide the optimal study design to examine 
the association between medication use and older driver crash involvement.64  
Recent epidemiological research has provided useful crash risk estimates by linking datasets 
including drug prescription, hospital admission due to motor vehicle crashes, police-reported 
crashes and health insurance information.37, 65 However, these studies have provided mixed results. 
Reasons for this may include small sample sizes, selection bias, and use of different outcome and 
exposure measures as well as failure to adjust for potential confounding factors. These confounders 
include health status, driving frequency, polydrug use and varying exposure to the medication. 
Inadequate assessment of medication compliance has also been identified as a significant limitation 
of pharmaco-epidemiological studies,7 although this objective information is thought to provide far 
more accurate data than information obtained via participant self-report.66-67 The most difficult 
confounding factor to control when examining associations between medications and crash risk is 
distinguishing the effects of the disease the medication is prescribed to treat, from the effects of the 
medication itself.24, 43, 68 Case-cross over designs where each subject acts as their own control 
represent an appropriate study design for future research in this area as they eliminate confounding 
due to fixed characteristics.55 
Additionally, both epidemiological and experimental studies may not be able to accurately 
predict the effects of psychotropic drugs under “real” driving conditions. A non-exhaustive list of key 
experimental and epidemiological studies conducted since 1988 are summarised in Tables 1 and 2. 
Recommendations 
Based on this review, the following recommendations are made for future research: 
 The impact of psychotropic medication use on driving performance and crash risk should 
continue to be investigated.  
 National and international collaboration on future studies should be encouraged. This 
should be supported by the development of international scientific guidelines and 
procedures. Methodologies and core variables need to be standardised in repeated studies. 
 Collaboration between Australian States’ and other countries’ impaired-driving legislation 
could give valuable insight into appropriate and potentially effective policy and legislative 
initiatives. 
 Large-scale, whole-population, epidemiological studies, such as data linkage studies aimed 
at investigating the individual and combined role of psychotropic medications in the risk of 
road traffic crashes, particularly in the older driver age group. This pharmaco-
epidemiological approach may be useful in identifying medications which pose a potential 
risk to traffic safety in populations with prescription and MVC databases. 
 Education campaigns and community based interventions should be developed and targeted 
at older drivers so that they become more aware of the possible impairment of cognitive 
function due to medications and driving. Future research should include clarification of drug-
induced driving impairment and risk perceptions related to impaired driving. 
Conclusion 
Since the number of older drivers is expected to increase significantly in the near future, issues 
related to safety for this group while ensuring their mobility needs are met is paramount. The 
literature supports the common sense approach that medication with strong sedative action taken 
in high doses has the highest potential for significant driver impairment. More research into chronic 
as well as acute use of psychotropic medication needs to be conducted on performance of driving 
related tasks. Emphasis should also be placed on newly emerging drugs with the potential for 
impairment. The findings of this review will provide road injury researchers and other stakeholders 
with comprehensive, in-depth information about Australian and international studies on road crash 
risk for older drivers taking medications which act on the central nervous system. Such information 
is fundamental for future research direction and essential to the development of evidence-based 
policy development. 
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Table1.  
SUMMARY OF KEY EXPERIMENTAL STUDIES 
 
EXPERIMENTAL STUDIES 
Author Study Design Study 
Population 
Sample Size Study 
Period 
Summary of Findings Medication P Value Country 






100 Jan 2004 – 
Mar 2005 
Non-randomised, comparative clinical study to evaluate effects 
of antidepressants on psychomotor performance related to 
driving. Results showed significant impairment in more than 
60% of patients and severe impairment in 16% who were 


















 13 male 
volunteers 
 Double blind four way crossover study to compare 
pharmacokinetic & psychomotor performance on 3 BZDs. 
Results showed significant impairment for alprazolam and 












 16 healthy 
drivers  
55-65 yrs 
 Double-blind balanced crossover study to assess residual 
effects of common hypnotics & placebo on older drivers’ 
performance. Results showed insignificant increase in collision 










18 volunteers 9subjects 
22-24 yrs 
 Double-blind, crossover, placebo controlled study to determine 
if alcohol and BZD use increases risk of night time driving. 
Diazepam p<0.05 Finland 






Older drivers showed poor baseline results but were less 
sensitive to Diazepam.  Psychomotor performance was 
unaffected by light conditions. 







 18 healthy 
volunteers 
 Double-blind, placebo controlled crossover study to investigate 
the subchronic effects of the drug on actual driving 
performance. Results showed impairment on lateral position 




Verster et al. 
2002 
Randomised double-
blind crossover study 
On-road driving test 
Computerised 
psychomotor test 
 20 healthy 
volunteers 
 Randomised, double-blind, placebo controlled crossover study 
to examine effects of alprazolam on driving ability. Results 









Table 2.  
SUMMARY OF KEY EPIDEMIOLOGICAL AND PHARMACO-EPIDEMIOLOGICAL STUDIES. 
 
EPIDEMIOLOGICAL STUDIES 
Author Study Design & 
Source of Data 
Study 
Population 
Sample Size Study 
Period 
Summary of Findings Medication Statistical Results Country 

















1987-1998 Case-control study examining the relation between BZD 
concentrations and impairment in apprehended drivers found that 
impaired subjects had significantly higher blood levels of diazepam, 
oxazepam or flunitrazepam than those not impaired. Further, the 
blood concentration of BZDs was the only characteristic which was 




















Apr 2004 - 
Sept 2005 
Crash incidence among drug exposed and unexposed subjects 
compared by standard incidence ratio. Patients receiving 





SIR= 3.7 [2.9-4.8] 
SIR= 2.8 [2.2-3.6] 
SIR= 1.1 [0.6-1.8] 
Norway 











Apr 2004 - 
Sept 2006 
Standardised incidence ratios calculated by comparing incidence of 
MVC during exposure to antidepressants with the incidence during 
non-exposure time. Results showed slight increased risk of MVC 





SIR= 1.4 [1.2-1.6] 
SIR= 1.6 [1.5-1.7] 
Norway 





Vic State Coroner’s 
Office 
NSW State Coroner’s 
Office 
Perth Coroner’s Office 
WA Toxicology  
3398 fatally 
injured drivers in 





Multi-centre case-control study to assess effect of alcohol & drug 
use on culpability. With regards to culpability neither BZDs nor 
opiates showed association. Strongest link was with cannabis and 
amphetamines or combination of drugs. Older drivers & drivers 






OR= 1.41 [0.7-2.9] 




Dubois et al. 2008 Case-control study 
FARS database  
NCSA database 
Blood & urine samples 
 
72026 drivers  
20+yrs  
involved in fatal 






Case-control study to examine impact of BZDs on crash 
responsibility in fatal MVC. Compared with drivers not taking BZDs, 
drivers taking intermediate or long half-life BZDs demonstrated 
increased odds of an unsafe driving action. Drivers taking short 






OR= 1.02 [0.73-1.42] 
OR= 1.53 [0.83-1.16] 
OR= 1.44 [1.25-1.66] 
Canada 










Apr 2004 - 
Sept 2005 
Crash incidence among prescription drug exposed and unexposed 
subjects compared by standard incidence ratio. Results showed an 






SIR= 2.0 [1.7-2.4] 
SIR= 2.9 [2.5-3.5] 
SIR= 3.3 [2.1-4.7] 
SIR= 1.5 [1.3-1.9] 
Norway 











Jan 2004 - 
Sept 2006 
Standard incidence ratios calculated by comparing incidence of 
MVC in exposed person-time to incidence of MVC in unexposed 
person-time. Results showed users of these hypnotics had clear 







SIR= 2.3 [2.0-2.7] 
 
SIR= 2.7 [1.8-3.9] 
SIR= 4.0 [2.4-6.4] 
Norway 
Hebert et al. 2007 Case-control & case-
crossover study 
SAAQ 
224 734 drivers 
67 - 84 yrs  
5579 cases 
12911 controls 
Jun 1990 – 
May 1993 
Used both case-control & case-crossover approaches to compare 
results on same study population. The 2 designs produced different 
results. Case-control found increased risk of MVC for elderly users 
of BZD but case-crossover showed no association. Authors suggest 
case-crossover should be used for intermittent users rather than 
long term users. 




Hooper et al. 2010 Case-control study 









Case-control study design used to examine association between 
prescribed medications & fatal MVC in military population. Cases & 
controls were matched. Findings suggest association between 







Longo et al. 2001 Cross-sectional study 




2,500 Apr– Aug 
1995 and 
Dec 1995 – 
Aug 1996 
Cross-sectional study showed there was a significant linear 
relationship between BZD concentration and crash risk. 
BZDs 2.7% drivers positive 
for BZD 
Australia 
McGwin et al. 2000 Case-control study 
Responsibility 




Jan 1 – Dec 
31 1996 
Population based case-control study to identify medical conditions 
and medications associated with at fault MVC. 3 classes of 
medications were positively associated with MVC: NSAIDs, ACE 






OR= 1.7 [1.0-2.6] 
OR= 5.2 [0.9-30.0] 
OR= 0.3 [0.1-1.0] 
USA 
Movig et al. 2004 Case-control study 










– Aug 2001 
Prospective observational case-control study to estimate the 
association between psychoactive drug use and MVC. Outcomes 
measures were OR & found increased risk for single use BZD, 
multiple drug use and drug-alcohol combinations. 
BZDs 
Opiates   
OR= 5.05 [1.82-14.04] 






Mura et al. 2003 Case-control study 
Blood & urine samples 
Patients of ED 








not involved in 
MVC 
Jun 2000 – 
Sept 2001 
Collaborative case-control study to determine prevalence of 
alcohol, licit & illicit drug use among drivers injured in MVC 
compared with control population. Outcomes confirmed high 
prevalence of use in population. Prevalence of medicines increased 
with age. BZDs most frequently observed medicine. 
Opiates 
BZDs  
OR= 8.2 [2.5-27.3] 
OR= 1.7 [1.2-2.4] 
France 






993 drivers 993 Oct 1998 – 
Sep 1999 
Data linkage study that linked blood samples of crash-involved 
drivers to accident records. Results showed no clear association 
between the use of alcohol, illicit drug and/or medicinal drug use 
and the severity of an accident. 





No association Netherlands 
Smink et al. 2008 Cohort study? 
Exposed/unexposed? 
Injury Severity Score, 
blood + urine samples 
106 injured car 
drivers 
106 May 2000 
– Aug 2001 
Cross sectional study explored the relationship between the use of 
psychoactive substances and the injury severity in a group of crash-
involved drivers. Results found no clear association between use of 
psychoactive substances and the severity of crash-related injury. 
BZDs 
 methadone, opiates 
 tricyclics 
antidepressants  
No association Netherlands 
Woratanarat et al. 
2009 
Case-control study  
Urine & blood 
samples, alcohol 





Case-control study to determine the relationship between alcohol 
use, psychoactive drug use and road traffic injury showed that 




OR= 3.4 [1.7-6.6] 
 
OR= 3.1 [1.5-6.3] 
Thailand 
breath tests from hospitals, 
849 matching 
controls recruited 
from gas stations 
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Appendix A1 A strategy framework for pedestrian and MMS safety** 
  Policy/Law 
Makers 
 









    
Conduct walkability & safe route audits 
in areas of high pedestrian activity 
    
Reduce travel speed  and traffic in high 
density pedestrian/ MMS  areas* 
    
Develop guidelines for adequate 
crossing times for older pedestrians* 
    
Improve maintenance of sidewalks, 
surrounds, and street lighting* 
    
Develop safer access for older people 
at bus and tram stops* 
    
Pedestrian-friendly enforcement of 
pedestrian traffic laws e.g. warnings for 
violations as jaywalking. 
    
Development of MMS registration 
system 
    
Education & Behavioural Strategies     
Prioritise pedestrians/ MMS users on 
the transport hierarchy – cultural shift 
    
Legitimate walking as an active form of 
transport in a sustainable society 
    
Raise awareness of pedestrian/ MMS 
users right of way traffic laws 
    
Raise awareness of vehicle speed & 
severity of pedestrian/ MMS users 
crash injury  
    
Raise awareness of older pedestrians 
reduced cognitive/ physical ability 
    
Raise awareness of the importance of 
pedestrian visibility and conspicuity 
    
Increase knowledge of risk & 
protective factors for pedestrian/ MMS 
users injury 
    
Increase knowledge of crossings 
(marked & unmarked) 
    
Comprehensive social marketing 
campaign for pedestrians/ MMS users. 
    
Target group and key stakeholder 
community consultation 
    
Targeted information sessions with 
older adults 
    
Use driving simulator to educate     
Increase knowledge of road rules and 
skills of mobility scooter users. 
    
Increase stakeholders knowledge of 
environmental modifications  
    
*Oxley & Fildes (2004) p.187 (J. Oxley, Fildes, et al., 2004)  
** no attempt here to grade the quality of evidence of effectiveness for these interventions/actions.  
